Hechos relevantes

GRIFOLS, S.A.

desde 01/07/1988 hasta 07/12/2023

• • 04/07/2019
  • 15:15
  • GRIFOLS, S.A.
  • R&D: new licenses, patents and registered trademarks
  • The U.S. Food and Drug Administration has approved Grifols´ new 20% subcutaneous immunoglobulin product, Xembify®, which is used to treat primary immunodeficiencies.
  • Número de registro: 279882
• • 05/06/2019
  • 14:44
  • GRIFOLS, S.A.
  • Strategic plans, profit forecasts and presentations
  • Reunión de inversores y analistas 2019
  • Número de registro: 278883
• • 24/05/2019
  • 15:15
  • GRIFOLS, S.A.
  • Announcements and resolutions of general shareholders meetings
  • General Shareholders´ Meeting 2019
  • Número de registro: 278588
• • 07/05/2019
  • 09:05
  • GRIFOLS, S.A.
  • Interim financial information
  • La sociedad remite información sobre los resultados del primer trimestre de 2019
  • Número de registro: 277812
• • 02/05/2019
  • 08:10
  • GRIFOLS, S.A.
  • Transmissions and purchases of capital undertakings
  • Exercise of call option over 51% of Interstate Blood Bank, Inc.
  • Número de registro: 277708
• • 16/04/2019
  • 08:27
  • GRIFOLS, S.A.
  • Announcements and resolutions of general shareholders meetings
  • Calling of the Ordinary General Shareholders´ Meeting 2019 of Grifols, S.A.
  • Número de registro: 277154
• • 29/03/2019
  • 14:08
  • GRIFOLS, S.A.
  • R&D: new licenses, patents and registered trademarks
  • AMBAR clinical trial results
  • Número de registro: 276585
  • • Relacionado con 270940 del 27/10/2018 (08:52)
• • 07/03/2019
  • 08:25
  • GRIFOLS, S.A.
  • Others on corporate transactions
  • Grifols and Shanghai RAAS Blood Products Co. Ltd. have signed an agreement for asset purchase by share issue
  • Número de registro: 275746
  • • Relacionado con 271763 del 21/11/2018 (18:01)
• • 28/02/2019
  • 08:28
  • GRIFOLS, S.A.
  • Information on P&L
  • Second half earnings report 2018
  • Número de registro: 275351
• • 28/02/2019
  • 08:25
  • GRIFOLS, S.A.
  • Interim financial information
  • La sociedad remite información sobre los resultados del segundo semestre de 2018
  • Número de registro: 275349